// App-Quantinova.ai

PL02.01 : Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

Researchers

Presenter

  • M. Johnson

Principal Investigators

  • A. Vasiliev

  • S. Kim

  • M. Hussein

  • F. Lim

  • C. Yang

  • H. Saito

  • X. Shi

  • L. Poole

  • S. Peters

  • E. Garon

Medical Centers

  • 4Astrazeneca, Cambridge/GB

  • Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne/CH

  • Yonsei Cancer Center, Seoul, Korea

  • Health Pharma Professional Research, Mexico City/MX

  • The University of Hong Kong, Pokfulam, Hong Kong

  • Chang Gung Memorial Hospital, Taoyuan City/TW

  • Federal State Budgetary Institution N.N. Blokhin Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, Moscow, Russia

  • Prince of Songkla University, Hat Yai, Thailand.

  • Florida Cancer Specialists – Sarah Cannon Research Institute, Leesburg/FL/US

  • Leningrad Regional Clinical Hospital, St. Petersburg, Russia

  • Kanagawa Cancer Center, Yokohama, Japan

  • AstraZeneca, Gaithersburg, MD

  • Queen Mary University of London, London/GB

  • Acinus, Kropyvnytskyi/UA

  • Instituto Nacional de Cancer-Inca, Rio de Janeiro/BR

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Asklepios Lung Clinic, Munich-Gauting/DE

  • Odessa Regional Oncological Dispensary, Odessa/UA

  • "private Health Institution "clinical Hospital" Rzd-Medicine", St Petersburg/RU

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Locations

  • United States

  • Mexico

  • Hong Kong

  • Taiwan

  • Thailand

  • Japan

  • United Kingdom

  • Spain

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Ticilimumab

  • Carboplatin

  • Gemcitabine

  • Durvalumab

  • Paclitaxel

  • Pemetrexed

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03164616

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved